These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 35233892)

  • 1. Risk of treatment discontinuation and psychiatric hospitalization associated with early dose reduction of antipsychotic treatment in first-episode schizophrenia: A nationwide, health insurance data-based study.
    Joo SW; Kim H; Jo YT; Ahn S; Choi YJ; Choi W; Park S; Lee J
    Psychiatry Clin Neurosci; 2022 May; 76(5):195-200. PubMed ID: 35233892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antipsychotic treatment and risk of discontinuation and hospitalization in first-episode schizophrenia: a nationwide population-based study.
    Joo SW; Kim H; Jo YT; Choi YJ; Ahn S; Lee J
    Psychol Med; 2023 Jan; 53(1):181-188. PubMed ID: 33855950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia.
    Mullins CD; Obeidat NA; Cuffel BJ; Naradzay J; Loebel AD
    Schizophr Res; 2008 Jan; 98(1-3):8-15. PubMed ID: 17596914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness of antipsychotic monotherapy and polypharmacy in schizophrenia patients with clozapine treatment: A nationwide, health insurance data-based study.
    Joo SW; Kim H; Jo YT; Ahn S; Choi YJ; Choi W; Park S; Lee J
    Eur Neuropsychopharmacol; 2022 Jun; 59():36-44. PubMed ID: 35550204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discontinuation of antipsychotics in individuals with first-episode schizophrenia and its association to functional outcomes, hospitalization and death: a register-based nationwide follow-up study.
    Stürup AE; Nordentoft M; Jimenez-Solem E; Osler M; Davy JW; Christensen TN; Speyer H; Albert N; Hjorthøj C
    Psychol Med; 2023 Aug; 53(11):5033-5041. PubMed ID: 35818718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 20-Year Nationwide Follow-Up Study on Discontinuation of Antipsychotic Treatment in First-Episode Schizophrenia.
    Tiihonen J; Tanskanen A; Taipale H
    Am J Psychiatry; 2018 Aug; 175(8):765-773. PubMed ID: 29621900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hospital utilization rates following antipsychotic dose reductions: implications for tardive dyskinesia.
    Caroff SN; Mu F; Ayyagari R; Schilling T; Abler V; Carroll B
    BMC Psychiatry; 2018 Sep; 18(1):306. PubMed ID: 30249218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time to discontinuation of first- and second-generation antipsychotic medications in the treatment of schizophrenia.
    Kreyenbuhl J; Slade EP; Medoff DR; Brown CH; Ehrenreich B; Afful J; Dixon LB
    Schizophr Res; 2011 Sep; 131(1-3):127-32. PubMed ID: 21576008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hospitalization risks in the treatment of schizophrenia: comparison of antipsychotic medications.
    Gianfrancesco F; Rajagopalan K; Wang RH
    J Clin Psychopharmacol; 2006 Aug; 26(4):401-4. PubMed ID: 16855459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antipsychotic Treatment Duration in Children and Adolescents: A Register-Based Nationwide Study.
    Varimo E; Aronen ET; Mogk H; Rättö H; Saastamoinen LK
    J Child Adolesc Psychopharmacol; 2021 Aug; 31(6):421-429. PubMed ID: 33739863
    [No Abstract]   [Full Text] [Related]  

  • 12. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial.
    Kahn RS; Fleischhacker WW; Boter H; Davidson M; Vergouwe Y; Keet IP; Gheorghe MD; Rybakowski JK; Galderisi S; Libiger J; Hummer M; Dollfus S; López-Ibor JJ; Hranov LG; Gaebel W; Peuskens J; Lindefors N; Riecher-Rössler A; Grobbee DE;
    Lancet; 2008 Mar; 371(9618):1085-97. PubMed ID: 18374841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients With Schizophrenia.
    Tiihonen J; Mittendorfer-Rutz E; Majak M; Mehtälä J; Hoti F; Jedenius E; Enkusson D; Leval A; Sermon J; Tanskanen A; Taipale H
    JAMA Psychiatry; 2017 Jul; 74(7):686-693. PubMed ID: 28593216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effectiveness of risperidone long-acting injectable vs first-generation antipsychotic long-acting injectables in schizophrenia: results from a nationwide, retrospective inception cohort study.
    Nielsen J; Jensen SO; Friis RB; Valentin JB; Correll CU
    Schizophr Bull; 2015 May; 41(3):627-36. PubMed ID: 25180312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia.
    Tiihonen J; Haukka J; Taylor M; Haddad PM; Patel MX; Korhonen P
    Am J Psychiatry; 2011 Jun; 168(6):603-9. PubMed ID: 21362741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delay in psychiatric hospitalization from the diagnosis of first-episode schizophrenia and its association with clinical outcomes and direct medical costs: a nationwide, health insurance data-based study.
    Joo SW; Kim H; Jo YT; Ahn S; Choi YJ; Choi W; Park S; Lee J
    BMC Psychiatry; 2022 Oct; 22(1):636. PubMed ID: 36209061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of clozapine response in patients with treatment-refractory schizophrenia: results from a Danish Register Study.
    Nielsen J; Nielsen RE; Correll CU
    J Clin Psychopharmacol; 2012 Oct; 32(5):678-83. PubMed ID: 22926603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TAILOR - tapered discontinuation versus maintenance therapy of antipsychotic medication in patients with newly diagnosed schizophrenia or persistent delusional disorder in remission of psychotic symptoms: study protocol for a randomized clinical trial.
    Stürup AE; Jensen HD; Dolmer S; Birk M; Albert N; Nielsen M; Hjorthøj C; Eplov L; Ebdrup BH; Mors O; Nordentoft M
    Trials; 2017 Sep; 18(1):445. PubMed ID: 28962668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world effectiveness of olanzapine and risperidone in the treatment of schizophrenia in Brazil over a 16-year follow-up period; findings and implications.
    Barbosa WB; Gomes RM; Godman B; Acurcio FA; Guerra Júnior AA
    Expert Rev Clin Pharmacol; 2021 Feb; 14(2):269-279. PubMed ID: 33331189
    [No Abstract]   [Full Text] [Related]  

  • 20. Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia.
    Tiihonen J; Taipale H; Mehtälä J; Vattulainen P; Correll CU; Tanskanen A
    JAMA Psychiatry; 2019 May; 76(5):499-507. PubMed ID: 30785608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.